Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Halpern

Showing results (221-230 of 250) with videos related to

Pageof 25
Sort By:
Leukemia|February 17, 2022
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasmAnna B Halpern, Megan Othus, Genevieve Alcorn, et al.
Blood Neoplasia|June 19, 2025
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasmSuravi Raychaudhuri, Ted A Gooley, Allegra Rasmussen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 23, 2021
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective AnalysisNathan J Moore, Megan Othus, Anna B Halpern, et al.
JAMA Oncology|May 9, 2024
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation TrialNoam E Kopmar, Kim Quach, Ted A Gooley, et al.
Autism : the International Journal of Research and Practice|May 10, 2021
Reduced engagement of visual attention in children with autism spectrum disorderChristopher S McLaughlin, Hannah E Grosman, Sylvia B Guillory, et al.
Leukemia & Lymphoma|March 10, 2023
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasmsNoam E Kopmar, Ted Gooley, Niall Curley, et al.
Science (New York, N.Y.)|January 30, 1970
Search for organic compounds in the lunar dust from the sea of tranquiblityC Ponnamperuma, K Kvenvolden, S Chang, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2019
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution ExperienceJason P Cooper, Sirin Khajaviyan, Stephen D Smith, et al.
NPJ Biofilms and Microbiomes|May 26, 2025
Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samplesSuravi Raychaudhuri, Hakan Gem, Kevin Chung, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Pageof 25

Showing results (221-230 of 250) with videos related to

Sort By:
Pageof 25
Leukemia|February 17, 2022
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasmAnna B Halpern, Megan Othus, Genevieve Alcorn, et al.
Blood Neoplasia|June 19, 2025
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasmSuravi Raychaudhuri, Ted A Gooley, Allegra Rasmussen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 23, 2021
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective AnalysisNathan J Moore, Megan Othus, Anna B Halpern, et al.
JAMA Oncology|May 9, 2024
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation TrialNoam E Kopmar, Kim Quach, Ted A Gooley, et al.
Autism : the International Journal of Research and Practice|May 10, 2021
Reduced engagement of visual attention in children with autism spectrum disorderChristopher S McLaughlin, Hannah E Grosman, Sylvia B Guillory, et al.
Leukemia & Lymphoma|March 10, 2023
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasmsNoam E Kopmar, Ted Gooley, Niall Curley, et al.
Science (New York, N.Y.)|January 30, 1970
Search for organic compounds in the lunar dust from the sea of tranquiblityC Ponnamperuma, K Kvenvolden, S Chang, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2019
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution ExperienceJason P Cooper, Sirin Khajaviyan, Stephen D Smith, et al.
NPJ Biofilms and Microbiomes|May 26, 2025
Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samplesSuravi Raychaudhuri, Hakan Gem, Kevin Chung, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Pageof 25